Vical shares surge on promising melanoma data; Pfizer acquires PAH drug; Aeterna poised for mid-stage cancer trial;

 @FierceBiotech:Mayo team discovers new diabetes drug class. Article | Follow @FierceBiotech

 @JohnCFierce: Merck is making a case today for its post-merger approval prospects. 5 new apps this year, 20 drugs in late stage.  Report | Follow @JohnCFierce

> Vical says that a mid-stage study of Allovectin-7 for metastatic melanoma proved promising. Researchers tracked a median survival rate of 19 months, which analysts said would be significant if researchers could deliver the same bottom line in a Phase III. The news sent its shares up 10 percent this morning. Story

> The FDA has approved Aeterna Zentaris' IND for its bladder cancer therapy, which paves the way for the developer to launch a mid-stage study later this year. Report

> Pfizer and Ergonex Pharma GmbH struck a deal in which Pfizer will acquire terguride, which is in development as a potential treatment for pulmonary arterial hypertension. Pfizer will support the completion of the ongoing Phase II trial for terguride and will have exclusive worldwide rights excluding Japan to commercialize terguride for the treatment of PAH. Ergonex will be eligible to receive milestone payments and royalties on the sales of terguride for PAH. Release

> NanoViricides has raised $5 million from a shelf offering. Release

And Finally... People who work three or more hours above the "normal" seven-hour work day in the UK suffer a 60 percent spike in risk for cardio issues. Release

Suggested Articles

Barely two years after paying up $263 million for the ex-Asia rights to BeiGene’s tislelizumab, Celgene is bowing out—to the tune of $150 million.

A University of Pennsylvania team discovered that a protein called TOX helps determine the fate of exhausted T cells in cancer and other diseases.

AstraZeneca is set to spend $630 million on R&D in South Korea over the next five years as part of a wider cooperative agreement.